Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Draft Guidance for Industry; Availability

The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry titled "Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage." This guidance assists sponsors in the design and analysis of studies that assess the influence of hepatic impairment on the pharmacokinetics and, where appropriate, the pharmacodynamics of a drug, including therapeutic biological products. When final, this guidance will represent FDA's current thinking. FDA is also withdrawing the guidance for industry titled "Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling" (May 2003), which formerly provided FDA's thinking relating to studies to assess the effect of hepatic impairment on the pharmacokinetics or pharmacodynamics of a drug and recommendations to include hepatic impairment information in labeling.

created_at
provider_category
Notice
providers
federal_register
created_by
scheduled-job:a5bbbe5ddcbdd49aeae94c04e3e1fefe5._scheduled_job.98281506-8306-45a9-b190-5e32261f7ddd
text_url
https://www.federalregister.gov/documents/full_text/text/2026/09/02/2026-17961.txt
themes
government, policy, regulation
source
Federal Register
provider_count
1
source_slug
federal-register
url
https://www.federalregister.gov/documents/2026/09/02/2026-17961/pharmacokinetics-in-patients-with-impaired-hepatic-function-study-design-data-analysis-and-impact-on
country
United States
language
English
org_id
0ac7c1ae-d6eb-4868-9eb4-96b085d4f7ba
dedup_key
f3be2a856a2f6ffee6d265f9a4dc34edabacc9fab3bf9ce3f4b7073f99315b38
last_modified_at
provider
federal_register
feed_section
Government
last_modified_by
scheduled-job:a5bbbe5ddcbdd49aeae94c04e3e1fefe5._scheduled_job.98281506-8306-45a9-b190-5e32261f7ddd
published_at

Related